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ABSTRACT
Knowledge transfer impacts the performance of deep learning — the
state of the art for image classification tasks, including automated
melanoma screening. Deep learning’s greed for large amounts of
training data poses a challenge for medical tasks, which we can alle-
viate by recycling knowledge from models trained on different tasks,
in a scheme called transfer learning. Although much of the best art
on automated melanoma screening employs some form of transfer
learning, a systematic evaluation was missing. Here we investigate
the presence of transfer, from which task the transfer is sourced, and
the application of fine tuning (i.e., retraining of the deep learning
model after transfer). We also test the impact of picking deeper
(and more expensive) models. Our results favor deeper models, pre-
trained over ImageNet, with fine-tuning, reaching an AUC of 80.7%
and 84.5% for the two skin-lesion datasets evaluated.
Index Terms— Melanoma screening, dermoscopy, deep learn-
ing, transfer learning
1. INTRODUCTION
From all skin cancers, melanoma represents just 1% of cases, but
75% of deaths1. Melanoma’s prognosis is good when detected early,
but deteriorates fast as the disease progresses. Automated tools may
play an important role in providing timely screening, helping doctors
focus on patients or lesions at risk, but the disease’s characteristics
— rarity, lethality, fast progression, and diagnosis subtlety — make
automated screening for melanoma particularly challenging.
Vast literature exists on automated melanoma screening [1], but
only in the past two years Deep Neural Networks (DNNs) [2] were
proposed to improve accuracies [1, 3, 4, 5, 6, 7, 8, 9, 10, 11]. DNNs
are the state of the art for image classification, but their use for med-
ical images is challenging, since those models require very large
training sets (from dozens of thousands, up to several million im-
ages) [12]. To bypass that difficulty, most current literature employs
transfer learning, a technique where a model trained for a given
source task is partially “recycled” for a new target task. Transfer
learning ranges from simply using the output of the source DNNs
as a feature vector, and training a completely new model (e.g., an
SVM) for the target task; until using a pre-trained source DNN to
initialize some of the weights of the target DNN, and training the
latter as usual [13].
Works employing DNNs for melanoma screening either train
a network from scratch [6, 7, 9], or transfer knowledge from Im-
ageNet [4, 5, 8, 10, 11]. The main difference between works is
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Fig. 1. Samples from datasets used here: (a) Atlas; (b) ISIC; (c)
Retinopathy; (d) ImageNet. Each row shows a sample from a differ-
ent class in the dataset. In this paper, datasets c and d are source
datasets used for transferring knowledge to target models trained
in the target task of melanoma screening, trained and evaluated in
datasets a and b.
the choice of DNN architecture and implementation framework —
the most common framework is Caffe [4, 8, 11], and the most com-
mon architectures are ResNet [10], DRN-101 [11], AlexNet [5], and
VGG-16 [8]. Schemes for artificially augmenting training data, and
for transferring learned knowledge also vary.
Segmenting the lesion before feature extraction is a common
choice for melanoma screening [8, 11], although DNNs generally
allow forgoing it [1, 4, 5, 8, 10, 14]. In this paper we forgo all pre-
processing steps, like lesion segmentation, or artifacts/hair removal.
Because transfer learning seems so central for successful appli-
cation of DNNs in melanoma screening, the main contribution of
this paper is studying it in more detail. Figure 1 illustrates both the
source datasets (Retinopathy and ImageNet) and the target datasets
used in our experiments. We attempt to answer the following ques-
tions: (1) What is the impact of transfer learning? Current art is
already convinced it helps, but by how much? (2) Is it better trans-
ferring from a related (medical) but smaller dataset, from a larger
unrelated (general) dataset, or from both? (3) Does retraining the
transferred network for the new task (known in the DNN literature
as fine tuning) help, and by how much? Our aim in this paper, thus,
is less pushing the envelope on model accuracies, and more increas-
ing our understanding on transfer learning. However, in the spirit of
showing that the alternatives evaluated are realistic, we contrast our
models to current art and show that they have similar performance.
Dermoscopic examination is complex, involving many types of
lesions, although automated screening is usually advanced as a bi-
nary decision, with melanoma as the positive class, and all other
lesions as the negative class. However, other skin cancers — notably
basal cell carcinomas — become a challenge for that model: should
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they just be put in the negative class with all other lesions? should
they be considered together with melanoma in a wholesale “malig-
nant” class? should they be removed altogether from the analysis?
or should they be analyzed as a third separate class? A second con-
tribution of this paper is evaluating the impact of such decisions.
2. DATA AND METHODS
A reference implementation with all source code for this paper is
available2. All software libraries mentioned here are linked there.
The datasets employed to train and test the target models
(melanoma screening) were the Interactive Atlas of Dermoscopy
(Atlas) [15], and the ISBI Challenge 2016 / ISIC Skin Lesion Anal-
ysis towards Melanoma Detection — Part 3: Disease Classification
(ISIC) [16]. Both are available, the former commercially, and the
latter free of charge.
The Interactive Atlas is a multimedia guide (Booklet + CD-
ROM) designed for training medical personnel to diagnose skin le-
sions. The CD-ROM contains 1,000+ clinical cases, each with at
least two images of the lesion: close-up clinical image, and dermo-
scopic image. Most images are 768 pixels wide× 512 high. Besides
the images, each case is composed of clinical data, histopathologi-
cal results, diagnosis, and level of difficulty. The latter measures
how difficult (low, medium and high) the case is considered to diag-
nose by a trained human. The diagnoses include, besides melanoma
(several subtypes), basal cell carcinoma, blue nevus, Clark’s nevus,
combined nevus, congenital nevus, dermal nevus, dermatofibroma,
lentigo, melanosis, recurrent nevus, Reed nevus, seborrheic kerato-
sis, and vascular lesions. There is also a small number of cases clas-
sified simply as ‘miscellaneous’. In this paper we employed only the
dermoscopic images, and included all cases except the acral lesions
(whose particular appearance poses very specific challenges). Some
images contained a black rectangular “frame” around the picture,
which we cropped automatically with ImageMagick3.
The ISBI Challenge 2016 / ISIC Skin Lesion Analysis towards
Melanoma Detection — Part 3: Disease Classification [16] is a sub-
set of 1,279 dermoscopy images from the International Skin Imaging
Collaboration, an international effort to improve melanoma diagno-
sis. The Challenge Dataset contains 900 images for training (273 be-
ing melanomas) and 379 for testing (115 being melanomas). Ground
truth lesion segmentations are available, but we did not use them.
The sources datasets employed for the transfer (pre-training of
the DNNs) were the Kaggle Challenge for Diabetic Retinopathy De-
tection dataset (Retinopathy)4, with a training set of 35,000+ high-
resolution retina images taken under varying conditions; and the
ImageNet Large Scale Visual Recognition Challenge 2012 dataset
(ImageNet), containing 1M training images labeled into 1,000 cat-
egories [3]. Both datasets are freely available. Our use of ImageNet
dataset was indirect — because training over it is so time consuming,
we opted for employing pre-trained source DNNs.
Figure 1 illustrates those four datasets.
With a single exception, all protocols were based upon the VGG-
M model proposed by Chatfield et al. [17]. We also run a single
comparison with the VGG-16 model [18] to evaluate the impact of
that deeper (and more expensive) architecture. Because the origi-
nal implementations are in MATLAB, which was not convenient for
our computational infrastructure, we reimplemented those models in
2https://sites.google.com/site/robustmelanomascreening
3http://www.imagemagick.org
4https://www.kaggle.com/c/diabetic-retinopathy-detection/data
Lasagne5 and Nolearn6.
In the experiments with transfer learning, we get the source
networks pre-trained on ImageNet, train them from scratch on
Retinopathy, or fine-tune on Retinopathy the model pre-trained on
ImageNet. In the baseline (control) experiment without transfer
learning, the networks are trained from scratch. In all networks, we
ignore the output layer and employ an SVM classifier to make the
decision. We did so for all experiments, including the fine-tuned
ones, to avoid introducing extraneous variability.
Whenever training is involved (when we fine-tune or train net-
works from scratch) we employ the technique of data augmenta-
tion, which consists in creating randomly modified training samples
from the existing ones. Data augmentation is almost always help-
ful [2, 17, 19], but particularly important when working with the
small datasets typical of medical tasks. Augmentation also brings
the opportunity to rebalance the classes, alleviating another problem
of medical tasks, where the positive class (melanomas) is usually
much smaller than the negative (benign lesions). To accomplish both
augmentation and balance, we only augment the minority classes
(Melanoma, Malignant, and Basal Cell Carcinoma, depending on
the experimental design).
The factors investigated are: transfer learning, which can be
no transfer (Atlas from scratch), from Retinopathy (Atlas from
Retinopathy), from ImageNet (Atlas from ImageNet), or double (At-
las from Retinopathy from ImageNet); and fine tuning, which can
be no FT (only the final SVM decision layer is trained in the target
models), or with FT (the target model is retrained for melanoma,
before the last layer is stripped and the SVM decision layer is
trained).
The protocol, in detail:
1. The weights of the networks are initialized as follows: (a) For
experiments without transfer, the weights of the network are ini-
tialized as an orthogonal matrix while the biases are initialized
as constants (0.05); (b) For experiments transferring from Ima-
geNet, the weights are loaded from an available pre-trained net-
work7 (converting from MATLAB format to Nolearn format);
(c) For experiments transferring from Retinopathy, the weights
are initialized as 1.a, and the network is trained for Retinopathy;
(d) For experiments with double transfer, the weights are loaded
from ImageNet as explained in 1.b, and the network is fine-tuned
for Retinopathy;
2. To reach the input size required by VGG, we resize all images to
224× 224 pixels, distorting the aspect ratio to fit when needed;
3. We “re-center” the input, as required by VGG, by subtracting the
mean of the training dataset. For networks transferred from Ima-
geNet, we used the (precalculated) mean that comes with VGG;
for the others, we calculated the mean of the images from the
respective training sets;
4. (Only for the protocols involving DNN training, either from
scratch, or with fine-tuning:) We strip the last layer of the source
network, add a new softmax layer to make the decision on the
skin lesion, and retrain the entire network. When training or
fine-tuning the model for Retinopathy, we proceed just like
training for Melanoma, except that output softmax units take 5
classes (as specified in Kaggle Competition) instead of 2 or 3
for Melanoma, or 1,000 for ImageNet. We balance the training
set by augmenting the data for the minority classes, applying a
5https://lasagne.readthedocs.io/en/latest/
6http://nolearndocs.readthedocs.io/en/latest/lasagne.html
7http://www.vlfeat.org/matconvnet/pretrained/
Table 1. Main results (AUC in %; FT: fine tuning). Surprisingly, transfer from another specific medical task (Retinopathy) is not effective,
even if preceded by transfer from a general task (ImageNet). Fine-tuning has major impact and should be considered a necessity. The choice
of labeling has a small and somewhat inconsistent impact, that might be due to chance.
Experimental Design No Transfer
From Retinopathy From ImageNet Double Transfer
no FT with FT no FT with FT with FT
Malignant vs. Benign 76.0 72.8 76.0 79.1 82.5 78.8
Melanoma vs. Benign 75.7 73.5 75.3 77.9 80.9 80.9
Melanoma vs. Carcinoma vs. Benign 73.0 71.4 72.8 79.4 83.6 81.8
Table 2. Results on ISIC, with VGG-16, with transfer learning from
ImageNet, with fine tuning. Baselines quoted from the ISIC 2016
competition website (competitors were originally ranked by mAP).
The results are provided to show that the models evaluated here are
realistic — in the sense that they are in the same ballpark of perfor-
mance as current art. All numbers in %.
AUC mAP ACC SE SP
1st place 80.4 63.7 85.5 50.7 94.1
2nd place 80.2 61.9 83.1 57.3 87.2
3rd place 82.6 59.8 83.4 32.0 96.1
This paper 80.7 54.9 79.2 47.6 88.1
random transformation (scaling, rotating, or flipping the images).
The random number generator is fixed at the very beginning of
each experiment, so that the training sequence is the same for
all experiments. That makes the comparisons fairer, reducing
uncontrolled variability. We train for 60 epochs with learning
rate 10−3, Nesterov momentum 0.1, and `2-regularization of
5 × 10−3. We perform a 10% stratified split of the training set
for validation. We keep the model that minimizes validation loss;
5. We extract the outputs of Group 7/Layer 19, which are vectors of
4, 096 dimensions, and use that output as a feature-vector to de-
scribe the images; we `2-normalize those vectors, and feed them
to a linear SVM classifier (Sklearn implementation) to make the
decision on the skin lesion. We separate 10% of the training set
for validation, to choose the SVM regularization parameter, opti-
mizing on the AUC.
We evaluated three experimental designs, varying the labeling
of the classes:
• Malignant vs. Benign lesions: melanomas and basal cell car-
cinomas were considered positive cases and all other diag-
noses were negative cases;
• Melanoma vs. Benign lesions: melanomas were positive
cases while all other diagnoses were negative ones, removing
basal cell carcinomas;
• Basal cell carcinoma vs. Melanoma vs. Benign lesions: here
we have three classes, with all other diagnoses under a single
Benign label.
For all designs we employed 5×2-fold cross-validation. Our
splits were semi-random, making an effort to balance as much as
possible diagnose distributions, to avoid unnecessary variability.
Our main metric was the Area Under the ROC Curve (AUC); for
the design with three classes, we computed three one-vs-one AUCs
and reported their average. For the experiment with the ISIC dataset
we also report the other measures employed in the competition. We
show the results on ISIC for reference purposes, to demonstrate that
the models being discussed here are in the same ballpark of perfor-
mance as the current state of the art (Table 2).
Table 3. Impact of the DNN architecture choice. A deeper model
(VGG-16) leads to best results, regardless of the experimental de-
sign. All experiments with transfer from ImageNet and fine tuning.
AUC (%)
Architecture Mal×Ben Mela×Ben Mela×Carc×Ben
VGG-M 82.5 80.9 83.6
VGG-16 83.8 83.5 84.5
Table 4. Results stratified by diagnosis difficulty of test images
(Low, Medium or High), for VGG-M, transferring from ImageNet,
with fine tuning. All: performance over the whole dataset. Low-,
medium-, and high- difficulty cases represent respectively 38.1, 36.3,
and 25.6% of the whole dataset.
AUC (%)
Experimental Design Low Medium High All
Malignant vs. Benign 93.7 82.5 58.8 82.5
Melanoma vs. Benign 93.0 79.6 56.6 80.9
3. RESULTS
Our results are in Table 1. Fine-tuning improves classification, both
when transferring from the small-but-related dataset (Retinopathy),
and when transferring from the large-but-unrelated task (ImageNet):
that agrees with current literature in DNNs, which almost always en-
dorses fine-tuning. Surprisingly, transfer learning from Retinopathy
(also a medical-image classification task) leads to worse results than
transferring from the general task of ImageNet, even in combination
with the latter. That might indicate that transferring from very spe-
cific tasks poses special challenges for overcoming the specialization
— even if the source and target tasks are somewhat related. The best
protocol we found was to simply transfer from ImageNet, with fine-
tuning. The comparison between DNN architectures shows that —
as usually observed for image classification — a deeper DNN per-
forms better (Table 3).
The experimental designs also showed differences in perfor-
mance: in general it was easier to either group Basal cell carcinomas
with Melanomas (Malignant vs. Benign), or to consider them as a
separate class (Melanoma vs. Carcinomas vs. Benign), than to ig-
nore them altogether (Melanoma vs. Benign). Those results suggest
that organizing the labels affects the difficulty of the task, but the
explanation for those aggregate numbers might be simply that Basal
cell carcinomas are easier to diagnose than Melanomas.
We show the results stratified by diagnose difficulty (as indicated
by the Atlas itself) in Table 4. Those results show that low-difficult
lesions can essentially be solved by current art with relatively high
confidence, while for difficult lesions performance is still little better
than chance.
4. CONCLUSIONS
Our results are consistent with current art on DNNs: transfer learn-
ing is a good idea, as is fine tuning. Our results also suggest, in line
with literature in DNNs, that deeper models lead to better results.
We expected that transfer learning from a related task (in our case,
from Retinopathy, another medical classification task) would lead to
better results, especially in the double transfer scheme, that had ac-
cess to all information from ImageNet as well. The results showed
the opposite, suggesting that adaptation from very specific — even
if related — tasks poses specific challenges. Still, we believe that
further investigation is needed (e.g., can another medical task show
better results? can another transfer scheme work?).
The results suggest that the experimental design is sensitive to
the choice of lesions to compose the positive and negative classes,
maybe due to the relative difficulty of identifying each of the types
of cancer evaluated (Melanomas and Carcinomas).
The results stratified by diagnose difficulty suggest that current
art can already deal with the lower and middle spectrum of difficulty,
especially considering that human doctors’ accuracies might be be-
tween 75-84% [20]. On the other hand, difficult lesions appear really
hard to diagnose. That suggests a referability framework as poten-
tially more fruitful than a diagnostics framework. Referring to the
doctor both the cases in which the model has high confidence for the
positive label, and the hard cases (for which the model has low con-
fidence), might be more achievable in the short term than attempting
to have high confidence for all cases.
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